CLINICAL RESEARCH: CORONARY ARTERY DISEASE AND CARDIAC METABOLISM
Myocardial Glucose Transport and Utilization in Patients With Type 2 Diabetes Mellitus, Left Ventricular Dysfunction, and Coronary Artery Disease
David P. Dutka, MD, FRCP*,*,
Michael Pitt, FRCP ,
Domenico Pagano, MD, FRCS,
Marco Mongillo, MD, PhD,
David Gathercole, BSc, PhD,
Robert S. Bonser, FRCS, FRCP and
Paolo G. Camici, MD, FESC, FACC, FAHA, FRCP
* Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
MRC Clinical Sciences Centre & National Heart and Lung Institute, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom.
Manuscript received January 12, 2006;
revised manuscript received April 11, 2006,
accepted June 8, 2006.
* Reprint requests and correspondence: Dr. David P. Dutka, Department of Cardiovascular Medicine, ACCI, Level 6, Box 110, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom. (Email: dpd24{at}cam.ac.uk).
OBJECTIVES: This research was designed to assess the effect of type 2 diabetes mellitus (T2DM) on myocardial glucose utilization in patients with heart failure secondary to coronary artery disease.
BACKGROUND: Patients with T2DM and coronary artery disease have an increased morbidity and mortality compared with patients with coronary artery disease without diabetes that may relate to a reduction in the ability of the myocardium to utilize glucose.
METHODS: Myocardial blood flow and glucose utilization were assessed during a hyperinsulinemic clamp by 18F-flurodeoxyglucose and positron emission tomography in 54 patients (19 with T2DM) with multivessel coronary artery disease and heart failure. In a subgroup of 18 patients, myocardial biopsies were obtained during coronary bypass surgery to assess glucose transporter (GLUT4) distribution and protein concentration, and compared with myocardium from transplant donor hearts.
RESULTS: Myocardial blood flow was similar in patients without diabetes and those with T2DM. Myocardial glucose utilization was lower in patients with T2DM (0.34 ± 0.16 vs. 0.47 ± 0.24 µmol·min–1·g–1, p = 0.0002) despite comparable plasma insulin concentrations and a higher blood glucose concentration. Extraction of glucose by the myocardium was reduced in patients with T2DM (7.1 ± 3.1% vs. 13.5 ± 5.2%, p < 0.01). Myocardial GLUT4 protein was similar in patients with and without T2DM (p = 0.75).
CONCLUSIONS: Patients with coronary artery disease and heart failure exhibit myocardial insulin resistance, and this is greater in those with T2DM. This may limit the ability of the myocardium in patients with T2DM to withstand ischemia and may contribute to the increased cardiovascular morbidity and mortality in such patients.
|
Abbreviations and Acronyms
| | CABG = coronary artery bypass grafting | | CAD = coronary artery disease | | FDG = 18F-flurodeoxyglucose | | FFA = free fatty acid | | GLUT4 = glucose transporter 4 | | LV = left ventricle/ventricular | | MBF = myocardial blood flow | | MGU = myocardial glucose utilization | | PET = positron emission tomography | | PPAR = peroxisome proliferator-activated receptor | | PTF = perfusable tissue fraction | | ROI = region of interest | | TACs = time-activity curves | | T2DM = type 2 diabetes mellitus |
|
Related Article
-
Time to Address the Cardiac Metabolic "Triple Whammy": Ischemic Heart Failure in Diabetic Patients
- John D. Horowitz and Jennifer A. Kennedy
J. Am. Coll. Cardiol. 2006 48: 2232-2234.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. A. Cook, A. Varela-Carver, M. Mongillo, C. Kleinert, M. T. Khan, L. Leccisotti, N. Strickland, T. Matsui, S. Das, A. Rosenzweig, et al.
Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction
Eur. Heart J.,
October 1, 2009;
(2009)
ehp396v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Thomson, M. P. Frenneaux, and J. C. Kaski
Antioxidant treatment for heart failure: friend or foe?
QJM,
May 1, 2009;
102(5):
305 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sacca
Heart Failure as a Multiple Hormonal Deficiency Syndrome
Circ Heart Fail,
March 1, 2009;
2(2):
151 - 156.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner and R. W. Nesto
Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection
Circulation,
May 13, 2008;
117(19):
2523 - 2533.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler
Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
93 - 102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Am J Physiol Heart Circ Physiol,
October 1, 2007;
293(4):
H2009 - H2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Gibbons, P. A. Araoz, and E. E. Williamson
The Year in Cardiac Imaging
J. Am. Coll. Cardiol.,
September 4, 2007;
50(10):
988 - 1003.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie
Metabolic Mechanisms in Heart Failure
Circulation,
July 24, 2007;
116(4):
434 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Horowitz and J. A. Kennedy
Time to Address the Cardiac Metabolic "Triple Whammy": Ischemic Heart Failure in Diabetic Patients
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2232 - 2234.
[Full Text]
[PDF]
|
|
|
|
